A detailed history of Captrust Financial Advisors transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 11,073 shares of IBRX stock, worth $49,717. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,073
Holding current value
$49,717
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.32 - $6.7 $36,762 - $74,189
11,073 New
11,073 $41,000
Q3 2021

Nov 16, 2021

BUY
$9.17 - $14.24 $17,606 - $27,340
1,920 New
1,920 $19,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.